1122 GMT - The U.S. Food and Drug Administration's request for a label warning about Guillain-Barre syndrome risk on GSK's respiratory syncytial virus shot Arexvy could negatively impact vaccine sales, Bryan Garnier Research analysts say in a note. While a causal link between vaccination and GBS-- a rapid-onset muscle weakness caused by the immune system-- hasn't been proven, seven GBS cases per million Arexvy doses were observed, according to the FDA. "We believe the observed GBS incidence very close to natural GBS incidence in the non-vaccinated population," the analysts say. Arexvy sales already declined double-digit in 2H of 2024, following the narrowed recommendation to a smaller age range and more at-risk patients, the analysts say. Shares fall 0.04% at 1359.50 pence.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
January 09, 2025 06:24 ET (11:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。